The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS).
Selina M. Luger
Research Funding - MethylGene
Casey Lee O'Connell
Research Funding - MethylGene
Virginia Klimek
Research Funding - MethylGene
Maureen A. Cooper
Research Funding - MethylGene
Emmanuel C. Besa
Research Funding - MethylGene
James M. Rossetti
Research Funding - MethylGene
Gregory K. Reid
Employment or Leadership Position - MethylGene
Rachel Humphrey
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
Robert E. Martell
Stock Ownership - MethylGene
Research Funding - MethylGene
Guillermo Garcia-Manero
Research Funding - MethylGene